F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics.

Rahbar, Kambiz; Afshar Oromieh, Ali; Bögemann, Martin; Wagner, Stefan; Schäfers, Michael; Stegger, Lars; Weckesser, Matthias (2018). F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. European journal of nuclear medicine and molecular imaging, 45(8), pp. 1329-1334. Springer 10.1007/s00259-018-3989-0

[img] Text
s00259-018-3989-0.pdf - Published Version
Restricted to registered users only until 15 March 2022.
Available under License Publisher holds Copyright.

Download (2MB) | Request a copy

PURPOSE PSMA-targeted PET in patients with prostate cancer (PCa) has a significant impact on treatment decisions. By far the most frequently used PSMA ligand isGa-labelled PSMA-11. However, due to the availability of larger amounts of activity,F-labelled PSMA ligands are of major interest. The aim of the present study was to evaluate the biodistribution and performance of the novelF-labelled ligand PSMA-1007 at two different time points. METHODS This retrospective analysis included 40 consecutive patients (mean age 68.7 ± 8.1 years) referred for PSMA PET/CT.F-PSMA-1007 PET/CT was performed for localization of biochemical relapse, primary staging or therapy follow-up. Circular regions of interest were placed on representative slices of the liver, spleen, kidney, abdominal aortic blood pool, bone marrow (fourth lumbar vertebral body), urinary bladder and gluteus muscle at 60 and 120 min after injection. In malignant lesions the maximum standardized uptake (SUV) was measured within volumes of interest at both time points. All SUVs at 60 min were compared with those at 120 min after injection. RESULTS The activity in the blood pool, urinary bladder and gluteus muscle was very low and decreased significantly over time (P < 0.001). Uptake in the liver, spleen and kidney showed a significant increase over time and uptake in the bone marrow remained stable. Overall, 135 PCa lesions were detected at 60 min and 136 lesions at 120 min after injection. The median SUVincreased significantly (P < 0.001) from 10.98 to 15.51 between 60 and 120 min. CONCLUSION PCa lesions show a significant increase inF-PSMA-1007 uptake at 120 min compared with 60 min after injection. In addition, accumulation of the tracer in the urinary bladder was very low leading to improved contrast of adjacent PCa lesions. Increasing accumulation in the liver may limit the sensitivity of the tracer in detecting liver metastases.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Afshar Oromieh, Ali

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1619-7070

Publisher:

Springer

Language:

English

Submitter:

Franziska Nicoletti

Date Deposited:

17 Apr 2018 17:00

Last Modified:

24 Oct 2019 21:47

Publisher DOI:

10.1007/s00259-018-3989-0

PubMed ID:

29541812

Uncontrolled Keywords:

PET/CT PSMA-1007 Prostate cancer

BORIS DOI:

10.7892/boris.113380

URI:

https://boris.unibe.ch/id/eprint/113380

Actions (login required)

Edit item Edit item
Provide Feedback